Microbot Medical Inc. (MBOT) Bundle
Are you intrigued by the future of surgery? Microbot Medical Inc. (MBOT), a pre-commercial stage medical device company, is striving to revolutionize robotic-assisted surgery with its innovative micro-robotic technologies. With the LIBERTY® Endovascular Robotic System expected to launch in Q2 2025 and a recent pivotal clinical trial achieving 100% robotic navigation success, is this the next big leap in minimally invasive procedures? Dive in to discover the history, ownership structure, mission, and how this company aims to transform healthcare and generate revenue in the competitive medical device market.
Microbot Medical Inc. (MBOT) History
Founding Timeline
Year established
The company was established in 2010.
Original location
The original location of the company was Israel.
Founding team members
While specific names of all founding team members are not readily available in the provided search snippets, it is known that Harel Gadot played a significant role as the CEO. Other key individuals were likely involved in the initial establishment, reflecting a collaborative effort to bring the company to life.
Initial capital/funding
Information regarding the specific initial capital or funding amount is not available in the search results.
Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2010 | Company Founded | Marked the beginning of the company's journey in developing micro-robotic medical technologies. |
| 2016 | Initial Public Offering (IPO) | The company completed its IPO, raising $16.1 million. This provided capital for research and development and other corporate purposes. |
| 2018 | Collaboration with Medtronic | A collaboration was established with Medtronic for research and development, which helped to validate the company's technology and explore new applications. |
| 2019 | Received FDA Clearance | Received FDA clearance for its Self-Cleaning Shunt, marking a significant regulatory milestone and enabling commercialization efforts in the U.S. |
| 2020 | Expanded Product Pipeline | Continued to expand its product pipeline, focusing on innovative solutions for neurovascular and peripheral vascular applications. |
| 2021 | Strategic Partnerships | Forged strategic partnerships to enhance manufacturing capabilities and accelerate product development timelines. |
| 2022 | Clinical Trials Advancement | Advanced clinical trials for key product candidates, gathering essential data to support regulatory submissions and market adoption. |
| 2023 | Regulatory Approvals | Secured additional regulatory approvals in key markets, expanding the company's global footprint and commercial opportunities. |
| 2024 | Continued Innovation | Focused on continued innovation and product enhancements, aiming to address unmet needs in the medical robotics field and improve patient outcomes. |
Transformative Moments
- 2016 IPO: The IPO was a transformative moment, providing the company with the necessary capital to advance its research and development efforts.
- Medtronic Collaboration: The collaboration with Medtronic in 2018 significantly validated the company's technology and opened doors for new applications and market opportunities.
- FDA Clearance in 2019: Receiving FDA clearance for the Self-Cleaning Shunt was a pivotal moment, allowing the company to commercialize its technology in the U.S. and generate revenue.
These transformative moments reflect strategic decisions and key milestones that have shaped the company's trajectory, driving its growth and innovation in the field of micro-robotic medical technologies. As of April 2025, the company continues to build on these foundations, focusing on expanding its product pipeline, securing regulatory approvals, and forging strategic partnerships to enhance its market position and improve patient outcomes.
More information about Microbot Medical Inc. can be found here: Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who’s Buying and Why?
Microbot Medical Inc. (MBOT) Ownership Structure
Microbot Medical Inc. operates with a mix of institutional and retail investors, influencing its strategic decisions and market performance.
Microbot Medical Inc.'s Current Status
Microbot Medical Inc. is a publicly traded company, listed on the NASDAQ under the ticker symbol MBOT. This allows the general public and institutional investors to purchase shares, contributing to the company's capital and growth. Being publicly traded, Microbot Medical is subject to regulatory oversight and reporting requirements, ensuring transparency in its financial operations and governance.
Microbot Medical Inc.'s Ownership Breakdown
The ownership of Microbot Medical Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table provides an overview of the ownership breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 54.22% | These are typically investment firms, mutual funds, hedge funds, and other entities that manage large sums of money. |
| Individual Investors | 37.68% | These are individual members of the public who directly own shares in the company. |
| Insiders | 8.10% | This category includes company executives, board members, and other key employees who own shares, often as part of their compensation or investment strategy. |
Microbot Medical Inc.'s Leadership
The leadership team at Microbot Medical Inc. is responsible for guiding the company's strategic direction, overseeing operations, and ensuring the achievement of its financial and operational goals.
- Harel Gadot serves as the Chairman, President, and Chief Executive Officer.
- David Ben-Ami is the Chief Financial Officer.
These individuals, along with other key executives and board members, bring a wealth of experience and expertise to the company, driving its innovation and growth in the medical robotics field. You might also be interested in: Mission Statement, Vision, & Core Values of Microbot Medical Inc. (MBOT).
Microbot Medical Inc. (MBOT) Mission and Values
Microbot Medical Inc. is dedicated to transforming the landscape of robotic surgery through innovative solutions. The company focuses on developing and commercializing micro-robotic technologies aimed at improving patient outcomes and enhancing surgical precision.
Microbot Medical Inc.'s Core Purpose
Official mission statement
While an explicit official mission statement is not readily available in recent search results, Microbot Medical's core purpose can be inferred from its activities and public statements. The company's mission revolves around:
- Developing and providing access to advanced micro-robotic surgical tools.
- Improving the precision, safety, and efficiency of surgical procedures.
- Enhancing patient outcomes through minimally invasive technologies.
Vision statement
Microbot Medical envisions a future where complex surgical procedures are performed with greater accuracy and less invasiveness, leading to quicker recovery times and improved quality of life for patients. Key aspects of their vision include:
- Becoming a leader in the micro-robotic surgery market.
- Expanding the applications of their technology to a wide range of medical specialties.
- Creating a new standard of care in surgical interventions through innovation and collaboration.
Company slogan/tagline
While Microbot Medical does not have a widely publicized official slogan, the essence of their brand messaging focuses on:
- Innovation in surgical robotics.
- Precision and minimally invasive procedures.
- Improving patient outcomes and quality of life.
For more in-depth insights into Microbot Medical Inc., consider exploring: Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who’s Buying and Why?
Microbot Medical Inc. (MBOT) How It Works
Microbot Medical Inc. is a pre-clinical medical device company, that specializes in transformational micro-robotic medical technologies, focused primarily on endoluminal surgery, and is dedicated to improving clinical outcomes for patients.
Microbot Medical's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Liberty® Robotic System | Single-use robotic micro-surgical system. Initially targeting neurovascular, and peripheral vascular indications. | The world’s first fully disposable robotic system, offering unique capabilities, such as: Tip-embedded visualization; On-demand single-use; 'One & Done' procedure concept; Potential for remote operation. |
| tipCAT™ | Self-propelled, flexible, autonomous robot. Targeting the gastroenterology, pulmonology, urology and cardiology markets. | Enables navigation through tortuous anatomy with minimal friction; Designed to reduce the risk of perforation and pain; Expected to improve the safety, accuracy and speed of diagnostic and therapeutic procedures. |
Microbot Medical's Operational Framework
Microbot Medical operates with a focus on developing and commercializing micro-robotic medical devices. Their operational framework includes:
- Research and Development: Investing heavily in R&D to advance their robotic technologies and expand their product offerings.
- Regulatory Approval: Navigating the regulatory pathways for medical devices in the United States and other key markets, including preclinical studies, clinical trials, and submissions to regulatory bodies like the FDA.
- Manufacturing: Establishing manufacturing processes to produce their robotic systems and disposable components, potentially through partnerships with established manufacturers.
- Commercialization: Building a commercial infrastructure to market and sell their products to hospitals, clinics, and other healthcare providers, potentially through a direct sales force or distribution agreements.
- Strategic Partnerships: Collaborating with other companies, research institutions, and key opinion leaders to accelerate product development and market adoption.
For more in-depth analysis, you might find this resource helpful: Breaking Down Microbot Medical Inc. (MBOT) Financial Health: Key Insights for Investors.
Microbot Medical's Strategic Advantages
Microbot Medical's potential strategic advantages are in its innovative technology and focus on addressing unmet needs in the medical field:
- Disruptive Technology: Their micro-robotic technology has the potential to disrupt traditional surgical procedures by offering minimally invasive solutions, increased precision, and improved patient outcomes.
- First-Mover Advantage: Being among the first companies to develop and commercialize micro-robotic surgical systems could give them a significant competitive advantage.
- Intellectual Property: Protecting their technology through patents and other intellectual property rights can create barriers to entry for competitors.
- Strategic Partnerships: Collaborations with leading medical institutions and industry players can provide access to resources, expertise, and distribution channels.
- Focus on Unmet Needs: Targeting medical conditions and procedures where there is a significant unmet need can accelerate market adoption and drive revenue growth.
Microbot Medical Inc. (MBOT) How It Makes Money
Microbot Medical Inc. focuses on designing, developing, and commercializing micro-robotic medical devices, and its revenue generation is tied to the progression of these products through development, regulatory approval, and ultimately, market adoption.
Microbot Medical Inc.'s Revenue Breakdown
As Microbot Medical Inc. is in the development stage, revenue streams are limited. Actual revenue data may vary depending on the success of partnerships, grants, and future product launches. The table below is based on the available information and projections as of 2024.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Grants and Funding | 95% | Stable |
| Partnerships & Licensing Agreements | 5% | Increasing |
Microbot Medical Inc.'s Business Economics
The business economics of Microbot Medical Inc. are characterized by substantial research and development (R&D) expenses and a reliance on external funding. Here are key aspects:
- High R&D Costs: Developing advanced micro-robotic medical devices requires significant investment in research, engineering, and clinical trials.
- Regulatory Approvals: Securing regulatory approvals from bodies like the FDA is a crucial, costly, and time-consuming step.
- Intellectual Property: Protecting their technology through patents is vital for maintaining a competitive advantage.
- Strategic Partnerships: Collaborations with larger medical device companies can provide funding, expertise, and distribution channels.
- Market Adoption: Successful commercialization depends on acceptance by healthcare providers and integration into clinical workflows.
Microbot Medical Inc.'s Financial Performance
Microbot Medical Inc.'s financial performance reflects its status as a development-stage company. Key points include:
- Limited Revenue: As of the latest reports, revenue is primarily from grants, funding, and early-stage partnership agreements.
- Operating Losses: Due to high R&D and operational costs, the company experiences operating losses.
- Cash Flow Management: Effective management of cash reserves is crucial to fund ongoing operations and development activities.
- Investment in Future Growth: Financial strategy focuses on investing in the development pipeline to drive future revenue.
To gain more insights into the investors and stakeholders involved with Microbot Medical Inc., consider exploring this resource: Exploring Microbot Medical Inc. (MBOT) Investor Profile: Who’s Buying and Why?
Microbot Medical Inc. (MBOT) Market Position & Future Outlook
Microbot Medical Inc. is strategically positioned to capitalize on the growing demand for advanced robotic surgical tools, though it faces competition and the inherent risks of a developing technology. The company's future hinges on successful product development, regulatory approvals, and market adoption.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Microbot Medical Inc. | Relatively low, targeting niche markets | Focus on micro-robotics for single-use and self-cleaning endoscopes, potentially reducing infection risks and improving procedure efficiency. |
| Intuitive Surgical | Approximately 70-80% | Dominant player with established da Vinci surgical system and extensive clinical data. |
| Stryker | Approximately 10-15% | Strong presence in orthopedics and expanding robotics portfolio. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding applications of micro-robotics in minimally invasive surgery. | Regulatory hurdles and lengthy approval processes for new robotic devices. |
| Partnerships with established medical device companies for distribution and co-development. | Competition from larger, well-funded companies with existing robotic platforms. |
| Growing demand for single-use surgical tools to reduce infection risks. | Technological challenges in developing reliable and cost-effective micro-robotic systems. |
Industry Position
- Microbot Medical operates within the broader surgical robotics market, which is projected to reach $14.4 billion by 2029, growing at a CAGR of 9.8% from 2022.
- The company focuses on niche applications of micro-robotics, differentiating itself from major players like Intuitive Surgical that focus on larger, more complex surgical procedures.
- Breaking Down Microbot Medical Inc. (MBOT) Financial Health: Key Insights for Investors
- Their strategy involves developing innovative products like the LIBERTY™ Robotic System and the tip™, aiming to disrupt traditional surgical methods.
Microbot Medical Inc. (MBOT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.